Compare Amgen, Inc. (AMGN) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs TotalEnergies SE — how do they compare? Amgen, Inc. trades at $415.52 (market cap $224.14B), while TotalEnergies SE trades at $87.16 (market cap $196.06B). The key difference: Amgen, Inc. and TotalEnergies SE are close in size by market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| AMGN | TTE | |
|---|---|---|
Market Cap | $224.14B | $196.06B |
Sector | Health | Energy |
52-Week High | $417.20 | $93.60 |
52-Week Low | $271.18 | $57.39 |
Enterprise Value | $267.45B | $227.06B |
Dividend Yield | 2.43% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
TotalEnergies SE (TTE) trades at $87.96, up 2.48% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while the company expands in renewables and gas projects. Valuation ratios like P/E of 11.01 and P/S of 0.98 appear attractive relative to sector peers.
The outlook is positive given strategic acquisitions and gas field developments, but risks include revenue declines and legal challenges. With a consensus price target of $94.00 and 57.58% buy ratings, the stock offers upside potential amid energy transition opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
